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Introduction
Stroke survivors have a 15-fold increased risk of a second stroke, with 17% experiencing a further cerebrovascular event in the five-year period following their first stroke. However, there are relatively few data on the use of antihypertensive agents in secondary prevention trials.
The MOrbidity and mortality after Stroke -Eprosartan compared with nitrendipine for Secondary prevention study (MOSES) tested the angiotensin receptor blocker (ARB) eprosartan in stroke partly because this agent had been found to improve post-stroke survival and to prevent end-organ failure in an experimental model (Barone FC, Coatney RW, Chandra S et al. Cardiovasc Res 2001; 50:525-37) . The comparator chosen was the calcium channel blocker (CCB) nitrendipine. In the Systolic Hypertension in Europe (Syst-Eur) trial, patients treated with nitrendipine had a 42% reduction in total stroke (p=0.003) and a 44% reduction in non-fatal stroke (p=0.007) compared to placebo (Staessen JA, Fagard R, Thijs L et al. Lancet 1997; 350:757-64) .
The hypothesis of the MOSES trial was that in hypertensive stroke patients, for the same level of blood pressure (BP) control, eprosartan would be more effective than nitrendipine in reducing cerebrovascular and cardiovascular mortality and morbidity.
Study Design
MOSES was set up using a prospective, randomised, open, blinded endpoint (PROBE) design. This meant that it had a steering committee, a blinded safety monitoring board and a blind endpoint committee. Patients were treated openly with the study medication but all endpoints were analysed by an independent endpoint committee consisting of two cardiologists and one neurologist. The study was coordinated from Cloppenburg and the statistical analysis was performed in Hamburg.
The combined primary endpoint was a composite of total mortality plus the total number of cardiovascular and cerebrovascular events, including recurrent events. Cerebral events were defined as intracerebral haemorrhage, recurrence of stroke, transient ischaemic attack (TIA) or prolonged reversible ischaemic neurological deficit (PRIND). Cardiovascular complications were defined as any cardiovascular event, including myocardial infarction and new heart failure. Predefined secondary endpoints were the individual elements of the primary endpoint plus an assessment of the functional status and cognitive function using the mini mental state examination (MMSE), Barthel Index and Rankin Scale. Mean duration of follow-up was 2.5 years. For inclusion, patients had to have hypertension requiring treatment, which was in this study confirmed by ambulatory blood pressure monitoring (ABPM). They also had to have cerebral ischaemia (TIA, PRIND or major stroke) or cerebral haemorrhage in the 24 months prior to study commencement, and a computerised tomography (CT) or magnetic resonance imaging (MRI) scan was required to confirm this. The principal exclusion criteria were severe carotid artery stenosis, age over 85 years, or severe cardiac failure, unstable angina or valve disease.
The study design is shown in figure 1. BP was measured at out-patient checks at 3, 6, 12, 18 and 24 months after inclusion in the study. ABPM and MMSE were performed at months 12, 24 and 48. The Rankin Scale and Barthel Index were repeated at 24 and 48 months, and adverse events were documented at each follow-up visit. A total of 1,405 patients were eligible for randomisation, of whom 710 were assigned an eprosartan-based regime and 695 a nitrendipine-based regime.
Patients were commenced on either eprosartan 600 mg or nitrendipine 10 mg daily. Patients who were already taking antihypertensive drugs had their medication rolled over directly to the study medication. Depending on the individual BP readings, the dose of drug was increased or other medication was added. These changes in medication were decided by the patient's own physician: a diuretic was recommended as the preferred choice but this was not a study requirement. At study end, 681 patients were eligible for analysis in the eprosartan group and 671 in the nitrendipine group.
Baseline characteristics are shown in table 1. There are no differences in age, gender, body mass index or time between qualifying event and entry into the study. BP measurements at study entry were also well matched.
As regards qualifying disease at study entry, there is a well balanced distribution (table 2) .
The two treatment groups were also well matched with respect to their functional status and cognitive function at study entry and with respect to their concomitant disease at study entry. Diabetes was present in about 37%, high blood lipids in about 53% and coronary heart disease in about 26%. Only 23% of patients in the study had no concomitant disease, and this might therefore be described as a high-risk population.
Results Figure 2 shows that the BP was lowered to the same extent in both treatment arms, and with a very similar timeframe. (This is important if the hypothesis is to be subject to scrutiny.) After three months, 75.5% of eprosartan patients and S13 A total number of 461 primary endpoints (including recurrent events) were decided by the endpoint committee. There were 206 endpoints in the eprosartan group and 255 in the nitrendipine group. This represents a statistically significant 21% risk reduction in favour of eprosartan treatment (p=0.014). Figure 3 shows the Kaplan-Meier curves for the composite primary endpoint. These start to diverge at 9-12 months, and the divergence becomes more pronounced with length of follow-up.
Details of cerebrovascular and cardiovascular events are shown in table 3. Figure 4 shows the Kaplan-Meier curves for cardiovascular events.
Additional Discussion
The Mini Mental State, modified Rankin Scale Score and Barthel Index scores were practically identical for both groups. Among those patients who did not have a primary endpoint during the study, there was a higher percentage of patients who had a measurable improvement in MMSE during follow-up compared to those who did suffer an endpoint. Conversely, among those patients who did have a primary endpoint, there was a higher percentage of patients with a measurable worsening in MMSE during follow-up compared to those who did not suffer an endpoint. This pattern held true both for cerebral and non-cerebral events, and may reflect more severe events prior to study inclusion in those patients who started with a low MMSE score. 
Figure 4
Kaplan-Meier curves for cardiovascular events in MOSES Patients who did not exhibit the usual nocturnal dipping of BP had a higher percentage of worsening MMSE scores compared to the "dippers". Also, more primary end points occurred among the non-dippers. Further analysis is needed in order to determine whether these differences are statistically significant but they are concordant with results from elsewhere that suggest that loss of the normal nocturnal dip is an additional risk factor for cardiovascular disease.
MOSES also shed some light on the degree to which the BP should be lowered in the secondary prevention of stroke. The best outcome occurred in patients whose systolic blood pressure (SBP) was in the range 120-140 mmHg. However, some caution is needed in interpretation of these figures since the number of patients with an SBP below 120 mmHg was very small. Nonetheless, it should perhaps be kept in mind that it might be better not to lower BP too far in secondary stroke prevention.
Conclusions
This was the first trial of two antihypertensive drugs in secondary prevention of stroke. It was conducted among a well defined population of hypertensive post-stroke patients, who were well matched in terms of baseline characteristics, BP and concomitant disease. Early and comparable control of BP was obtained and a high percentage of patients in both treatment arms obtained target BP values. Eprosartan had advantages in respect of the combined primary endpoint, all cerebrovascular events and first cardiovascular events. 
